Roche's CEA (carcinoembryonic antigen assay) products "breach Immunomedics' EU patent"
This article was originally published in Clinica
Executive Summary
An appeals court in the Netherlands ruled on June 27 that Roche's sale of carcinoembryonic antigen assay (CEA) kits in Europe infringe two European patents held by US company Immunomedics. CEA is one of the most widely used markers for colorectal and other cancers, said Morris Plains, New Jersey-based Immunomedics, as it welcomed the outcome of the latest round of patent infringement claims involving itself and Roche.
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.